The anti-inflammatory effects of BET and HDAC inhibitors are widely suggested to be novel approaches to the therapy of inflammation-linked or -driven disorders, including atherosclerosis, multiple sclerosis, or sepsis [117,118]. Here, HDAC9 is linked to Sepsis.